Received Dec 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | 1 | CA20C1 | OT / LA |
| TDAP | TDAP (ADACEL) | SANOFI PASTEUR | UNK | — | OT |
administered DAPTACEL (DTAP) to a patient needed ADACEL (TDAP) with no reported adverse event; Initial information received on 04-Dec-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 12-year-old male patient who was administered DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] (dtap) to a patient needed DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] (tdap) with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Meningococcal vaccine A/C/Y/W conj (tet tox) (Menquadfi); HPV vaccine (HPV vaccine); and Influenza vaccine all for prophylactic vaccination. On 04-Dec-2025 at 11:30, the patient received a dose 1 dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE Suspension for injection of frequency: once, strength: standard, lot CA20C1 and expiry date: 28-Feb-2026 via intramuscular route in the left deltoid for Immunization who needed adacel (tdap) with no reported adverse event (wrong product administered) (latency: on same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Menquadfi; HPV vaccine; Influenza vaccine